A TB-500 COA should identify the exact peptide material rather than rely on the trade name alone, connect its test sample to the supplier lot, and report the methods and results reviewed. Confirm whether the stated material is a fragment or a full-length peptide; similar naming does not establish identical sequence, composition or analytical evidence.
Key points
- Use an unambiguous material description, not only “TB-500.”
- Resolve fragment and full-length naming before interpreting mass data.
- Check observed identity evidence and sample-to-lot mapping.
- Keep chromatographic purity distinct from measured content.
This guide addresses document review, not biological effects. Compare the TB-500 research-library listing with the supplier’s current specification and lot-linked analytical report. If the exact identity remains unclear, that is a documentation gap to resolve before laboratory acceptance.
Establish the material description first
Ask for the stated sequence or other unambiguous material identifier, declared form and relevant modifications. Where a fragment is supplied, the description should distinguish it from a full-length peptide. A familiar catalog name does not make those materials interchangeable.
Do not infer exact identity from a paper discussing thymosin beta-4 or from a supplier’s use of similar terminology. A literature reference and a batch report answer different questions: one describes a study; the other provides analytical evidence about a defined sample.
Match the report to the supplier lot
Collect the supplier lot identifier, laboratory sample identifier, report number, report version and tested material description. These identifiers do not need to have identical formats, but the mapping should be documented. The COA field guide explains the general fields.
Check whether the submitted sample was bulk material or a final filled presentation. A bulk identity report may support the upstream material’s characterization without establishing final-container quantity. A report for a single material is not automatically a report for a blend that contains it.
Read identity evidence against the exact designation
Mass-spectrometry results should be interpreted against the material actually claimed, including relevant modifications and mass-reporting conventions. A calculated reference value without an observed measurement is not independent analytical confirmation.
Intact mass can support consistency with an expected material, but it may not distinguish every isomer or sequence arrangement. If the identity question requires more discrimination, the laboratory should explain which additional evidence is appropriate. Do not claim a generic mass match proves every aspect of sequence and structure.
Separate chromatographic purity from measured content
A chromatographic area percentage reports the relative signal under stated method conditions. It is not automatically a quantitative measurement of peptide content in each container. Water, counterions and other constituents can require separate characterization. The purity-percentage guide explains why a high area percentage cannot answer every composition question.
When a quantitative content result is included, check its method, units, sample description and reporting basis. Where no such result is supplied, record the gap instead of inferring content from the purity headline or catalog presentation.
Use a short discrepancy checklist
- Does the specification clearly identify a fragment or full-length material where relevant?
- Do the report and label describe the same material and supplier lot?
- Are observed analytical data distinguished from theoretical values?
- Does the testing scope cover the sample stage and attributes being claimed?
- Are questions about naming or report revisions resolved in writing?
Ambiguity does not automatically establish mislabeling. It does mean the laboratory lacks enough evidence for a confident interpretation. Keep material with unresolved identity questions out of active research according to the laboratory’s own review procedures.
Document the conclusion without extrapolating
Save the exact material description, lot mapping, report, reviewer, supported attributes and unresolved items. The research-methods overview provides related context for weighing analytical evidence.
A documentation review should not turn a test result into a claim about recovery, biological performance or suitability beyond the stated research specification. Its value is narrower and more useful: it makes clear which material was tested and what the evidence supports.
A practical review table
| Document item | Useful evidence | Unresolved alternative |
|---|---|---|
| Material designation | Exact identifier, relevant sequence or modification description | Trade-name shorthand alone |
| Expected versus observed | Clear reference basis and measured assignment | Reference value copied without observed data |
| Lot mapping | Connection between supplier lot and test sample | A report for similarly named material |
| Sample stage | Bulk or final-container description | Unstated coverage extended to all presentations |
Laboratory competence and the identity claim are separate checks. ISO/IEC 17025 provides the laboratory-competence framework; an accreditation claim should be checked against its scope and does not make an ambiguous material description precise.
Worked example: reading a hypothetical report
Hypothetical example only: A fictional supplier labels lot EX-TB-A “TB-500.” Report DEMO-TB-A describes sample DEMO-SAMPLE-E using a specific fragment designation, while a separate specification refers to full-length material. These invented identifiers illustrate a naming conflict, not the characteristics of an actual product.
Do not resolve the conflict by selecting whichever document contains a favorable result. Ask the supplier for the exact intended material description and a controlled explanation of which specification applies to EX-TB-A. Ask the issuer whether the reported identity assignment relates to that same description.
If a corrected record confirms the fragment designation, retain the superseded document and the explanation. Review observed identity evidence against the corrected description, not against a full-length reference from an unrelated source. If the discrepancy remains unresolved, keep the conclusion bounded: the file does not yet establish an unambiguous identity for the supplied lot. A high purity number would not fix that naming problem.
Common mistakes
- Using TB-500 as if it were an unambiguous sequence identifier in every source.
- Borrowing a full-length reference to interpret a report for a fragment.
- Treating intact mass as complete proof of sequence or stereochemistry.
- Letting a consistent purity figure distract from inconsistent material descriptions.
Related documentation guides
authenticate the report and check revisions; evaluate an independent testing claim.
Frequently asked questions
What should a TB-500 COA show?
It should describe the exact material, connect the supplier lot to the tested sample and identify the methods and results. When a fragment or modification is relevant, that distinction should be clear enough to interpret the identity evidence.
Is TB-500 always the same as thymosin beta-4?
Do not assume identical meaning from informal naming. Review the exact declared peptide and supporting documentation. Similar terminology can conceal differences that matter to analytical interpretation; a trade-name match is not a sequence confirmation.
Can a mass result resolve ambiguous naming?
It can provide supporting evidence, but it must be interpreted against a clear proposed identity and reporting convention. A standalone number without material context does not settle every sequence, modification or structural question.
Can a TB-500 COA also cover a combination material?
Not automatically. A combination has a different declared composition. Request documentation that identifies the components and explains which analytical results support the combination, rather than extending a single-material certificate without justification.
What should I do with conflicting fragment and full-length descriptions?
Retain both records and request a documented correction identifying which description applies to the supplier lot. Do not silently reconcile them. If the conflict remains unresolved, record an identity-evidence gap in the laboratory’s acceptance review.
Research use only: Research materials discussed here are for qualified laboratory research only, not for human or veterinary use. This article concerns documentation and analytical review, not personal-use instructions.

